The remainder of 2025 will be busy for Vir Biotechnology as it strives to successfully pivot to developing cancer and infectious disease therapies.

Chronic obstructive pulmonary disease (COPD) is the third leading cause of death globally and remains a major public health burden. It is currently defined as FEV1/forced vital capacity (FVC) below ...

FibroBiologics, Inc. (Nasdaq: FBLG) ('FibroBiologics”), a clinical-stage biotechnology company with 275+ patents issued and pending with a focus on the development of therapeutics and potential cures ...

OPKO Health, Inc. (NASDAQ: OPK) reports business highlights and financial results for the three and six months ended June 30, 2025. Highlights from the second quarter of 2025 and recent weeks include ...

Clinical trials are the backbone of medical innovations, shaping the therapies and diagnostics that define modern healthcare. Designing and executing a successful trial involves more than scientific ...

SHELTON, CT / ACCESS Newswire / July 30, 2025 / NanoViricides, Inc., a publicly traded company (NYSE Amer.:NNVC) (the ...

New clinical trial results reveal gedatolisib significantly improves progression-free survival in advanced HR+/HER2– breast ...

New insights highlight how prostate cancer is now managed as a chronic disease, with emerging treatments and real-world data offering renewed hope for patients.

If drug developers are allowed to skip this step, it will mean that, in the near future, the first living body a new drug is ever tested in will be a human.

Celcuity stock (NASDAQ: CELC), a clinical-stage biotechnology company, experienced an extraordinary 3x surge in a single ...

Nations that lead in clinical trials get earlier access to breakthrough therapies, shape global regulatory norms, and ...